XML 43 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Note 19 - Related Party Transactions
 12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

NOTE 19. RELATED PARTY TRANSACTIONS      

 

Related Party Revenue 

 

The following table summarizes information about the Company’s related party revenue and cost of goods sold during the years ended December 31, 2021, 2020 and 2019, respectively (in thousands): 

 

  

Year Ended December 31,

 
  

2021

  

2020

  

2019

 

Related party revenue:

            

NeutroPhase

 $368  $524  $209 

Licensing

  —   —   41 

Total related party revenue

 $368  $524  $250 
             

Cost of goods sold

            

NeutroPhase

 $325  $384  $176 

Licensing

  —   —   — 

Total related party expenses

 $325  $384  $176 

 

Related party accounts receivable was $0.1 million and $0.2 million as of December 31, 2021 and December 31, 2020, respectively.

 

Other Related Party Expenses 

 

During the year ended December 31, 2021, the Company purchased KN95 Masks through an affiliate of China Pioneer. As of December 31, 2021, there was no related party account payable as compared to related party accounts payable of $8 thousand as of December 31, 2020.

 

The following table summarizes information about the Company’s other related party expenses excluding stock-based compensation during the years ended December 31, 2021, 2020 and 2019, respectively (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

  

2019

 

Commissions to China Kington related to:

            

OP Private Placement

 $—  $—  $— 

June 2019 Private Placement

  —   —   144 

August 2019 Private Placement

  —   —   162 

Exercise of June 2019 Warrants

  —   41   — 

Exercise of 2019 Foreign Warrants

  —   160   — 

Promissory Note to Pioneer Pharma (Hong Kong) Company Ltd.

  —   —   20 

Total commissions to China Kington

  —   201   326 

Board Director Bob Wu consulting fee

  —   50   83 

Total related party expenses

 $—  $251  $409 

 

On November 17, 2020, the Company entered into a consulting agreement with Eric Wu. Eric Wu is Partner and Senior Vice President of China Kington and the brother of Bob Wu, who serves on the Company’s Board of Directors. Pursuant to the Agreement, Eric Wu acted as a consultant to the Company in support of product expansion efforts as well as in potential financings and other transaction opportunities. The term of the Agreement was for twelve months. As consideration for his services, the Company granted Eric Wu options exercisable for 300,000 shares of the Company’s common stock under the Company’s 2017 Omnibus Incentive Plan with an exercise price equal to the Company’s closing stock price on the date of the grant and vesting on the one year anniversary of the grant date. Stock-based compensation expense of $152 thousand and $15 thousand was recorded for the year ended December 31, 2021 and 2020, respectively, related to Eric Wu’s options.